BHLHE40

Across TCGA pan-cancer cohorts, BHLHE40 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BHLHE40’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BHLHE40 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BHLHE40 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

HNSC, LSCC, and CCRCC are the cancer types where BHLHE40 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BHLHE40 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	−0.305	<.001	9	view →
LSCC	All	All	+0.230	<.001	5	view →
CCRCC	Male	III,IV	+0.773	.006	1	view →
PDAC	Female	All	+0.527	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BHLHE40–HNSC

Open the HNSC breakdown →